| our findings suggest NTRK3 is a conditional tumor suppressor gene that is commonly inactivated in colorectal cancer by both epigenetic and genetic mechanisms | colorectal, |
| TrkC tumor suppressor activity requires Hey1 and p53. | None |
| ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. | breast, |
| TrkC-miR2 as a novel regulator of Wnt signaling, which might be a candidate oncogenic colorectal cancer biomarker. | colorectal, |
| Report a novel subset of high-grade uterine sarcomas with features reminiscent of soft tissue fibrosarcoma and characterized by oncogenic activation of Trk through recurrent NTRK gene fusions. | fibrosarcoma,uterine, |
| A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation. | None |
| A subset of ALK-negative inflammatory myofibroblastic tumour (IMT) have rearrangement of ROS1, ETV6 or NTRK3 as a possible oncogenic mechanism. | None |
| we demonstrate the expression of the ETV6-NTRK3 fusion oncogene in a small subset of inflammatory myofibroblastic tumors | None |